NYSEAMERICAN:ISR

Isoray Stock Forecast, Price & News

$0.70
0.00 (0.00 %)
(As of 07/26/2021 12:00 AM ET)
Add
Compare
Today's Range
$0.69
$0.71
50-Day Range
$0.38
$0.54
52-Week Range
$0.35
$2.81
Volume407,557 shs
Average Volume728,721 shs
Market Capitalization$99.35 million
P/E RatioN/A
Dividend YieldN/A
Beta1.03
30 days | 90 days | 365 days | Advanced Chart
Receive ISR News and Ratings via Email

Sign-up to receive the latest news and ratings for Isoray and its competitors with MarketBeat's FREE daily newsletter.


Isoray logo

About Isoray

Isoray, Inc., through its subsidiary, IsoRay Medical, Inc., develops, manufactures, and sells isotope-based medical products and devices for the treatment of cancer and other malignant diseases in the United States and internationally. The company produces CS-1 Cesium-131 brachytherapy seeds for the treatment of prostate, brain, lung, head and neck, gynecological, pelvic/abdominal, and colorectal cancers, as well as ocular melanoma. It sells its products to facilities or physician practices that utilize multiple surgical facilities at which primarily prostate brachytherapy procedures are performed. Isoray, Inc. was founded in 1998 and is headquartered in Richland, Washington.

Headlines

See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous


MarketRank

Overall MarketRank

1.36 out of 5 stars

Medical Sector

1643rd out of 4,434 stocks

Surgical & Medical Instruments Industry

175th out of 362 stocks

Analyst Opinion: 3.4Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











Isoray (NYSEAMERICAN:ISR) Frequently Asked Questions

Is Isoray a buy right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Isoray in the last year. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Isoray stock.
View analyst ratings for Isoray
or view top-rated stocks.

What stocks does MarketBeat like better than Isoray?

Wall Street analysts have given Isoray a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Isoray wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Isoray's next earnings date?

Isoray is scheduled to release its next quarterly earnings announcement on Thursday, September 16th 2021.
View our earnings forecast for Isoray
.

How were Isoray's earnings last quarter?

Isoray, Inc. (NYSEAMERICAN:ISR) released its quarterly earnings data on Thursday, May, 13th. The healthcare company reported ($0.01) EPS for the quarter, hitting the consensus estimate of ($0.01). The healthcare company had revenue of $2.60 million for the quarter, compared to the consensus estimate of $2.44 million. Isoray had a negative trailing twelve-month return on equity of 15.33% and a negative net margin of 36.52%.
View Isoray's earnings history
.

How has Isoray's stock price been impacted by COVID-19 (Coronavirus)?

Isoray's stock was trading at $0.6706 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, ISR stock has increased by 4.7% and is now trading at $0.7023.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for ISR?

4 analysts have issued twelve-month price objectives for Isoray's stock. Their forecasts range from $1.00 to $3.00. On average, they expect Isoray's stock price to reach $2.03 in the next year. This suggests a possible upside of 189.5% from the stock's current price.
View analysts' price targets for Isoray
or view top-rated stocks among Wall Street analysts.

Who are Isoray's key executives?

Isoray's management team includes the following people:
  • Ms. Lori A. Holmes-Woods, CEO & Director (Age 59, Pay $392.94k)
  • Mr. William A. Cavanagh III, Chief R&D Officer (Age 55, Pay $258.8k)
  • Mr. Jonathan R. Hunt, CFO & Co-Principal Financial Officer (Age 54)
  • Ms. Jennifer Streeter, COO & VP of HR (Age 51)
  • Mr. Mark J. Austin CPA, Controller, Co-Principal Financial & Principal Accounting Officer and Corp. Sec. (Age 34)
  • Ms. Krista Cline, Sr. Director of Operations & Corp. Sec. (Age 39)

Who are some of Isoray's key competitors?

What other stocks do shareholders of Isoray own?

What is Isoray's stock symbol?

Isoray trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "ISR."

How do I buy shares of Isoray?

Shares of ISR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Isoray's stock price today?

One share of ISR stock can currently be purchased for approximately $0.70.

How much money does Isoray make?

Isoray has a market capitalization of $99.35 million and generates $9.68 million in revenue each year. The healthcare company earns $-3,450,000.00 in net income (profit) each year or ($0.05) on an earnings per share basis.

How many employees does Isoray have?

Isoray employs 53 workers across the globe.

What is Isoray's official website?

The official website for Isoray is isoray.com.

Where are Isoray's headquarters?

Isoray is headquartered at 350 Hills St Ste 106, RICHLAND, WA 99354-5511, United States.

How can I contact Isoray?

Isoray's mailing address is 350 Hills St Ste 106, RICHLAND, WA 99354-5511, United States. The healthcare company can be reached via phone at (509) 375-1202 or via email at [email protected]


This page was last updated on 7/27/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.